Developing Innovative Cancer Immunotherapies

Learn about our science


Developing innovative internally discovered small molecule drug candidates as well as antibody candidates that target immuno-oncology pathways

learn more

We’re Hiring!

Arcus Biosciences is an exciting young company founded on the vision of creating new cancer therapeutics through the translation of unexploited insights in immunology.

learn more

Press Releases
Recent News

Arcus Biosciences and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Lead Programs in Triple-Combination Studies

learn more


Adenosine dreams fueling new approaches in cancer; Arcus embarks on phase I

By Randy Osborne, Staff Writer

Although Merck & Co. Inc. continues to chalk up investor-pleasing sales with Keytruda (pembrolizumab) and Bristol-Myers Squibb Co. (BMS) keeps doing well with Opdivo (nivolumab), researchers have yet to strike upon the best combinations with other agents.

Keep Reading


Phase 1
Phase 1b Dose Esc.

AB928 (A2aR/A2bR Antagonist)

AB928 + AB122 (anti-PD-1)
AB928 + Chemotherapy

AB680 (Small Molecule CD73i)

AB680 (IV)
Regulatory filing Q3
AB680 (oral)

Antibody Programs

AB122 (anti-PD-1 Antibody)
Enrolling in solid tumors
AB154 (anti-TIGIT Antibody)
Regulatory filing submitted

Other Small Molecules

AB745 (A2aR Antagonist)
Arginase inhibitor
Lead ID

Arcus has significant expertise in immunology, medicinal chemistry, biochemistry, enzymology, pharmacology, and structural biology.

Meet Our Leadership